JPH06502069A - ワクシニアベクター，ワクシニア遺伝子及びその発現生成物 - Google Patents

ワクシニアベクター，ワクシニア遺伝子及びその発現生成物

Info

Publication number: JPH06502069A
Authority: JP; Japan
Prior art keywords: virus; vector; sequences; gene; vaccinia
Prior art date: 1990-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP3517131A

Other languages

English (en)

Japanese (ja)

Inventor

スミス，ジェフリー　リレイ

Original Assignee

リンクスベイル　リミティド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-10-26

Filing date

1991-10-28

Publication date

1994-03-10

1991-10-28 Application filed by リンクスベイル　リミティド filed Critical リンクスベイル　リミティド

1994-03-10 Publication of JPH06502069A publication Critical patent/JPH06502069A/ja

Status Pending legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims description 131
239000013598 vector Substances 0.000 title claims description 24
206010046865 Vaccinia virus infection Diseases 0.000 title description 22
208000007089 vaccinia Diseases 0.000 title description 22
230000014509 gene expression Effects 0.000 title description 6
241000700605 Viruses Species 0.000 claims description 79
241000700618 Vaccinia virus Species 0.000 claims description 60
102000004169 proteins and genes Human genes 0.000 claims description 54
210000004027 cell Anatomy 0.000 claims description 50
239000002773 nucleotide Substances 0.000 claims description 41
125000003729 nucleotide group Chemical group 0.000 claims description 41
239000012634 fragment Substances 0.000 claims description 34
101150039990 B13R gene Proteins 0.000 claims description 30
101100232885 Cowpox virus (strain Brighton Red) CPXV209 gene Proteins 0.000 claims description 30
101100004091 Vaccinia virus (strain Copenhagen) B15R gene Proteins 0.000 claims description 30
101100340726 Vaccinia virus (strain Western Reserve) VACWR197 gene Proteins 0.000 claims description 30
108020004414 DNA Proteins 0.000 claims description 25
108090000765 processed proteins & peptides Proteins 0.000 claims description 25
102000004196 processed proteins & peptides Human genes 0.000 claims description 21
101150023320 B16R gene Proteins 0.000 claims description 20
108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
101100316831 Vaccinia virus (strain Copenhagen) B18R gene Proteins 0.000 claims description 20
101100004099 Vaccinia virus (strain Western Reserve) VACWR200 gene Proteins 0.000 claims description 20
229920001184 polypeptide Polymers 0.000 claims description 19
238000000034 method Methods 0.000 claims description 17
230000003612 virological effect Effects 0.000 claims description 16
229960005486 vaccine Drugs 0.000 claims description 13
230000027455 binding Effects 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 12
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 10
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 9
238000012217 deletion Methods 0.000 claims description 9
230000037430 deletion Effects 0.000 claims description 9
230000002163 immunogen Effects 0.000 claims description 6
210000001744 T-lymphocyte Anatomy 0.000 claims description 5
239000013603 viral vector Substances 0.000 claims description 5
239000002260 anti-inflammatory agent Substances 0.000 claims description 4
238000002405 diagnostic procedure Methods 0.000 claims description 4
238000004113 cell culture Methods 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
239000013604 expression vector Substances 0.000 claims description 2
230000000415 inactivating effect Effects 0.000 claims description 2
238000012360 testing method Methods 0.000 claims description 2
239000000126 substance Substances 0.000 claims 5
238000009007 Diagnostic Kit Methods 0.000 claims 2
108091027544 Subgenomic mRNA Proteins 0.000 claims 2
238000009169 immunotherapy Methods 0.000 claims 2
108700028369 Alleles Proteins 0.000 claims 1
239000012491 analyte Substances 0.000 claims 1
229940124599 anti-inflammatory drug Drugs 0.000 claims 1
230000004968 inflammatory condition Effects 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 51
150000001413 amino acids Chemical group 0.000 description 31
239000000047 product Substances 0.000 description 29
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 21
208000015181 infectious disease Diseases 0.000 description 19
239000013612 plasmid Substances 0.000 description 18
235000001014 amino acid Nutrition 0.000 description 15
108091026890 Coding region Proteins 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
239000002245 particle Substances 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 10
230000028993 immune response Effects 0.000 description 9
238000004458 analytical method Methods 0.000 description 8
208000037516 chromosome inversion disease Diseases 0.000 description 8
235000018417 cysteine Nutrition 0.000 description 8
102000003886 Glycoproteins Human genes 0.000 description 7
108090000288 Glycoproteins Proteins 0.000 description 7
102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 7
108090001090 Lectins Proteins 0.000 description 7
102000004856 Lectins Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
238000013519 translation Methods 0.000 description 7
230000005847 immunogenicity Effects 0.000 description 6
108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
230000029812 viral genome replication Effects 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 5
108090000695 Cytokines Proteins 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
102000000589 Interleukin-1 Human genes 0.000 description 5
108010002352 Interleukin-1 Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
150000001720 carbohydrates Chemical class 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
230000028709 inflammatory response Effects 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
239000002523 lectin Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
244000052769 pathogen Species 0.000 description 5
239000000523 sample Substances 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
206010062016 Immunosuppression Diseases 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
238000007792 addition Methods 0.000 description 4
230000002238 attenuated effect Effects 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
150000001945 cysteines Chemical class 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
239000002243 precursor Substances 0.000 description 4
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
101001108363 Gallus gallus Neuronal cell adhesion molecule Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
229940121363 anti-inflammatory agent Drugs 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
238000010367 cloning Methods 0.000 description 3
YNKFCNRZZPFMEX-XHPDKPNGSA-N desmopressin acetate trihydrate Chemical compound O.O.O.CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 YNKFCNRZZPFMEX-XHPDKPNGSA-N 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229940028441 minirin Drugs 0.000 description 3
230000035772 mutation Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
241000557626 Corvus corax Species 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
108010087819 Fc receptors Proteins 0.000 description 2
102000009109 Fc receptors Human genes 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
241000238556 Megabalanus rosa Species 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
235000014443 Pyrus communis Nutrition 0.000 description 2
101150003725 TK gene Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
241000700647 Variola virus Species 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002528 anti-freeze Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
125000001165 hydrophobic group Chemical group 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
229940100601 interleukin-6 Drugs 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
229960000951 mycophenolic acid Drugs 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229940127557 pharmaceutical product Drugs 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000004853 protein function Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000012770 revaccination Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
241000894007 species Species 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000017613 viral reproduction Effects 0.000 description 2
SXOUIMVOMIGLHO-AATRIKPKSA-N (E)-3-(indol-2-yl)acrylic acid Chemical compound C1=CC=C2NC(/C=C/C(=O)O)=CC2=C1 SXOUIMVOMIGLHO-AATRIKPKSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
ZXXTYLFVENEGIP-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurine-2,6-dione Chemical compound O=C1NC(N)=NC2=C1NC=N2.O=C1NC(=O)NC2=C1NC=N2 ZXXTYLFVENEGIP-UHFFFAOYSA-N 0.000 description 1
101150064109 4b gene Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
101150067954 B15R gene Proteins 0.000 description 1
101150006352 B18R gene Proteins 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
101100096502 Danio rerio spring gene Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241000701533 Escherichia virus T4 Species 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
101150008942 J gene Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000238589 Megabalanus Species 0.000 description 1
241000702321 Microvirus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101001108365 Mus musculus Neuronal cell adhesion molecule Proteins 0.000 description 1
101100096504 Mus musculus Spring1 gene Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
240000001857 Phyllostachys elegans Species 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
101710163364 Protein amalgam Proteins 0.000 description 1
101150090155 R gene Proteins 0.000 description 1
101100426090 Rattus norvegicus Trim9 gene Proteins 0.000 description 1
101710145752 Serine recombinase gin Proteins 0.000 description 1
102000008847 Serpin Human genes 0.000 description 1
108050000761 Serpin Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
101100096505 Xenopus laevis spring1 gene Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003141 anti-fusion Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003491 array Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
238000010218 electron microscopic analysis Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000035784 germination Effects 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
230000003067 hemagglutinative effect Effects 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
102000002467 interleukin receptors Human genes 0.000 description 1
108010093036 interleukin receptors Proteins 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229940031348 multivalent vaccine Drugs 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
239000003001 serine protease inhibitor Substances 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
229960004854 viral vaccine Drugs 0.000 description 1
230000001018 virulence Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
108700026215 vpr Genes Proteins 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Plant Pathology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

JP3517131A 1990-10-26 1991-10-28 ワクシニアベクター，ワクシニア遺伝子及びその発現生成物 Pending JPH06502069A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB909023352A GB9023352D0 (en)	1990-10-26	1990-10-26	Vaccinia vectors,vaccinia genes and expression products thereof
GB9023352.9		1990-10-26
PCT/GB1991/001882 WO1992007944A1 (fr)	1990-10-26	1991-10-28	Vecteur de la vaccine, genes de la vaccine et leurs produits d'expression

Publications (1)

Publication Number	Publication Date
JPH06502069A true JPH06502069A (ja)	1994-03-10

Family

ID=10684414

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP3517131A Pending JPH06502069A (ja)	1990-10-26	1991-10-28	ワクシニアベクター，ワクシニア遺伝子及びその発現生成物

Country Status (5)

Country	Link
EP (1)	EP0555291A1 (fr)
JP (1)	JPH06502069A (fr)
CA (1)	CA2094821A1 (fr)
GB (1)	GB9023352D0 (fr)
WO (1)	WO1992007944A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002502802A (ja) *	1997-12-02	2002-01-29	ニューララブリミテッド	アミロイド形成疾患の予防および処置
JP2013544782A (ja) *	2010-10-15	2013-12-19	バヴァリアン・ノルディック・アクティーゼルスカブ	組み換え改変ワクシニアウイルスアンカラインフルエンザワクチン

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9204780D0 (en) *	1992-03-05	1992-04-15	Smith Geoffrey L	Vaccinia vectors,vaccinia genes,and expression products thereof;pharmaceuticals,reagents and methods
DK0758397T3 (da) *	1994-04-29	2005-10-10	Baxter Healthcare Sa	Rekombinante poxvira med fremmede polynucleotider i essentielle regioner
US7285526B2 (en)	1995-07-14	2007-10-23	Meiogen Biotechnology Corporation	Interferon antagonists useful for the treatment of interferon related diseases
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
AR052051A1 (es)	2004-12-15	2007-02-28	Neuralab Ltd	Anticuerpos ab humanizados usados en mejorar la cognicion
DK2567976T3 (en)	2005-03-23	2017-10-23	Genmab As	ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYLOMA
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
WO2009017467A1 (fr)	2007-07-27	2009-02-05	Elan Pharma International Limited	Traitement de maladies amyloïdogéniques
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
WO2014172309A2 (fr) *	2013-04-18	2014-10-23	The United States Of America As Represented By The Secretary Of The Army, On Behalf Of The United	Compositions thérapeutiques pour neutraliser les interférons de type i, et procédés d'utilisation

1990
- 1990-10-26 GB GB909023352A patent/GB9023352D0/en active Pending
1991
- 1991-10-28 EP EP91918806A patent/EP0555291A1/fr not_active Withdrawn
- 1991-10-28 WO PCT/GB1991/001882 patent/WO1992007944A1/fr not_active Application Discontinuation
- 1991-10-28 CA CA002094821A patent/CA2094821A1/fr not_active Abandoned
- 1991-10-28 JP JP3517131A patent/JPH06502069A/ja active Pending

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002502802A (ja) *	1997-12-02	2002-01-29	ニューララブリミテッド	アミロイド形成疾患の予防および処置
JP2006131639A (ja) *	1997-12-02	2006-05-25	Neuralab Ltd	アミロイド形成疾患の予防および治療剤
JP2013544782A (ja) *	2010-10-15	2013-12-19	バヴァリアン・ノルディック・アクティーゼルスカブ	組み換え改変ワクシニアウイルスアンカラインフルエンザワクチン

Also Published As

Publication number	Publication date
WO1992007944A1 (fr)	1992-05-14
EP0555291A1 (fr)	1993-08-18
CA2094821A1 (fr)	1992-04-27
GB9023352D0 (en)	1990-12-05

Publication	Publication Date	Title
JPH06502069A (ja)	1994-03-10	ワクシニアベクター，ワクシニア遺伝子及びその発現生成物
Afonso et al.	1992	Characterization of p30, a highly antigenic membrane and secreted protein of African swine fever virus
Kaplan et al.	1996	Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus.
JP3368902B2 (ja)	2003-01-20	ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質
CN111675765B (zh)	2024-02-06	靶向冠状病毒spike的武装嵌合抗原受体细胞及制备方法和应用
HU230364B1 (hu)	2016-03-29	Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
EP4205762A1 (fr)	2023-07-05	Vaccin à adn amélioré pour sars-cov-2
US20150139999A1 (en)	2015-05-21	Interferon antagonists, antibodies thereto, and associated methods of use
CN115605223A (zh)	2023-01-13	抗非洲猪瘟病毒感染的疫苗
CN112245568A (zh)	2021-01-22	E184l基因缺失减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
JPH06508994A (ja)	1994-10-13	日本杉花粉からのアレルゲン性蛋白質及びペプチド
WO2023020623A1 (fr)	2023-02-23	Protéine de fusion et nanoparticule de protéine de spicule pour la prévention ou le traitement d'infections à coronavirus, et leur utilisation
JPH10504724A (ja)	1998-05-12	ボルナ病ウイルスの配列、神経系疾患のための診断薬および治療薬
JPH02502878A (ja)	1990-09-13	蛋白質およびその製造方法、ｄｎａ配列、抗体およびその適用、ポックスウィルス、形質転換されたまたは感染された細胞ならびにトキソプラズマ症の予防に有用な医薬品製剤
JPH03164181A (ja)	1991-07-16	豚コレラウイルスワクチン
Reubel et al.	2005	Experimental inoculation of European red foxes with recombinant vaccinia virus expressing zona pellucida C proteins
JP2004528010A (ja)	2004-09-16	免疫モジュレーションのための核酸およびポリペプチド
CN1904053B (zh)	2011-08-10	一种日本血吸虫多价dna疫苗和制备方法
CN111533791B (zh)	2022-02-15	一种钩端螺旋体黏附蛋白rvWFA3-2的制备方法和应用
WO2003072781A1 (fr)	2003-09-04	Galectine anti-acarienne
RU2812356C1 (ru)	2024-01-30	Интегративный плазмидный вектор PVEAL3-GP-MARV-Trim, обеспечивающий синтез и секрецию рекомбинантного поверхностного гликопротеина GP вируса Марбург в клетках млекопитающих, рекомбинантный штамм клеточной линии CHO-K1-GP-MARV и рекомбинантный белок GP-MARV, продуцируемый указанным штаммом клеточной линии CHO-K1-GP-MARV и используемый для получения иммунобиологических препаратов
AU662295B2 (en)	1995-08-31	Cytokine production
CN100398156C (zh)	2008-07-02	用于预防鸡球虫病的免疫调节型dna疫苗
CN112592410B (zh)	2021-05-11	犬腺病毒基因工程亚单位疫苗、其制备方法及应用
CN111732667B (zh)	2020-11-20	小反刍兽疫病毒基因工程亚单位疫苗